4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy characterized by hemolysis, platelet consumption, and renal injury. Eculizumab, a mAb that blocks complement activity, has been successfully used in aHUS.

          Related collections

          Author and article information

          Journal
          J. Thromb. Haemost.
          Journal of thrombosis and haemostasis : JTH
          1538-7836
          1538-7836
          Sep 2014
          : 12
          : 9
          Affiliations
          [1 ] Medicina Interna, Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
          Article
          10.1111/jth.12615
          24853860
          © 2014 International Society on Thrombosis and Haemostasis.

          Comments

          Comment on this article